Sponsor-Investigators

Deepak Kilari

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Status

Open to Accrual

Cancer Types

Bladder

Locations

Froedtert & the Medical College of Wisconsin, John Theurer Cancer Center at Hackensack Meridian Health, Missouri, New Jersey, New York, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Tennessee, University of Rochester Medical Center - Wilmot Cancer Institute, Vanderbilt-Ingram Cancer Center, Virginia, Virginia Commonwealth University, Wisconsin